Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey. more
Time Frame | THAR | Sector | S&P500 |
---|---|---|---|
1-Week Return | 0.46% | -3.39% | 0.2% |
1-Month Return | -8.02% | -1.92% | 2.72% |
3-Month Return | -27.09% | -10.54% | 7.31% |
6-Month Return | -29.22% | -4.47% | 10.44% |
1-Year Return | -71.67% | 4.06% | 27.53% |
3-Year Return | -99.83% | 0.94% | 30.88% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Profit | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 994.54K | 1.52M | 3.21M | 6.88M | 9.46M | [{"date":"2019-12-31","value":10.52,"profit":true},{"date":"2020-12-31","value":16.07,"profit":true},{"date":"2021-12-31","value":33.93,"profit":true},{"date":"2022-12-31","value":72.78,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (994.54K) | (1.81M) | (3.21M) | (6.88M) | (9.46M) | [{"date":"2019-12-31","value":-99454000,"profit":false},{"date":"2020-12-31","value":-180835100,"profit":false},{"date":"2021-12-31","value":-320801700,"profit":false},{"date":"2022-12-31","value":-688193800,"profit":false},{"date":"2023-12-31","value":-945522000,"profit":false}] |
Total Non-Operating Income/Expense | (606.01K) | (855.55K) | 170.10K | (3.18M) | 272.25K | [{"date":"2019-12-31","value":-222.59,"profit":false},{"date":"2020-12-31","value":-314.25,"profit":false},{"date":"2021-12-31","value":62.48,"profit":true},{"date":"2022-12-31","value":-1168.95,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (1.53M) | (2.42M) | (2.21M) | (8.47M) | (9.32M) | [{"date":"2019-12-31","value":-152547400,"profit":false},{"date":"2020-12-31","value":-241737100,"profit":false},{"date":"2021-12-31","value":-220664300,"profit":false},{"date":"2022-12-31","value":-847318200,"profit":false},{"date":"2023-12-31","value":-931909400,"profit":false}] |
Income Taxes | - | (42.67K) | 831.28K | (228.49K) | (15.26K) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-5.13,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-27.49,"profit":false},{"date":"2023-12-31","value":-1.84,"profit":false}] |
Income After Taxes | - | (2.37M) | (3.04M) | (8.24M) | (9.30M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-237470500,"profit":false},{"date":"2021-12-31","value":-303792000,"profit":false},{"date":"2022-12-31","value":-824469700,"profit":false},{"date":"2023-12-31","value":-930383000,"profit":false}] |
Income From Continuous Operations | (1.53M) | (2.42M) | (2.21M) | (8.47M) | (9.32M) | [{"date":"2019-12-31","value":-152547400,"profit":false},{"date":"2020-12-31","value":-241737100,"profit":false},{"date":"2021-12-31","value":-220664300,"profit":false},{"date":"2022-12-31","value":-847318200,"profit":false},{"date":"2023-12-31","value":-931909400,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (1.53M) | (2.42M) | (2.21M) | (8.47M) | (9.32M) | [{"date":"2019-12-31","value":-152547400,"profit":false},{"date":"2020-12-31","value":-241737100,"profit":false},{"date":"2021-12-31","value":-220664300,"profit":false},{"date":"2022-12-31","value":-847318200,"profit":false},{"date":"2023-12-31","value":-931909400,"profit":false}] |
EPS (Diluted) | - | - | (0.45) | (0.25) | (10.57) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-45,"profit":false},{"date":"2022-12-31","value":-25,"profit":false},{"date":"2023-12-31","value":-1057,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
THAR | |
---|---|
Cash Ratio | 2.14 |
Current Ratio | 2.35 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
THAR | |
---|---|
ROA (LTM) | -165.08% |
ROE (LTM) | -454.53% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
THAR | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.43 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.57 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
THAR | |
---|---|
Trailing PE | 0.04 |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 1.07 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Tharimmune Inc. (THAR) share price today is $2.09
Yes, Indians can buy shares of Tharimmune Inc. (THAR) on Vested. To buy Tharimmune Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in THAR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Tharimmune Inc. (THAR) via the Vested app. You can start investing in Tharimmune Inc. (THAR) with a minimum investment of $1.
You can invest in shares of Tharimmune Inc. (THAR) via Vested in three simple steps:
The 52-week high price of Tharimmune Inc. (THAR) is $8.41. The 52-week low price of Tharimmune Inc. (THAR) is $1.83.
The price-to-earnings (P/E) ratio of Tharimmune Inc. (THAR) is 0.0357
The price-to-book (P/B) ratio of Tharimmune Inc. (THAR) is 1.07
The dividend yield of Tharimmune Inc. (THAR) is 0.00%
The market capitalization of Tharimmune Inc. (THAR) is $3.24M
The stock symbol (or ticker) of Tharimmune Inc. is THAR